Running chemotherapeutic drug screens on tumor biopsies ex vivo has the potential to increase patient survival by personally matching them to the drug which is the most effective against their particular tumor.
W.E. Moerner and Adam Cohen have patented the Anti-Brownian ELectrokinetic trap (ABEL trap) which can trap, measure, and manipulate sub-micron objects (e.g. single molecules) in solution at ambient temperature.